Home > Dr. George Demetri Discusses Regorafenib for Patients with GIST Trial Results
Sarcoma

Dr. George Demetri Discusses Regorafenib for Patients with GIST Trial Results

Published Online: January 4th 2013

George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, discusses results from a phase III trial investigating the oral targeted therapy regorafenib for patients with gastrointestinal stromal tumors (GIST) that developed a resistance to imatinib or sunitinib.


George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, discusses results from a phase III trial investigating the oral targeted therapy regorafenib for patients with gastrointestinal stromal tumors (GIST) that developed a resistance to imatinib or sunitinib.

Find out more at http://www.onclive.com/conference-coverage/asco-2012/Dr-Demetri-Discusses-Reg…

Related Videos In Sarcoma
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar